The manufacturer of the "miracle weight-loss drug," Nuohe Nordic, has raised its full-year operating profit guidance to an increase of 40%-46%.
Novo Nordisk has raised its full-year operating profit (at constant exchange rates) guidance to a growth of 40%-46%, higher than analysts' expectations of 37.5%. The company had originally forecasted...
Novo Nordisk has raised its full-year operating profit (at constant exchange rates) guidance to a growth of 40%-46%, higher than analysts' expected growth of 37.5%. The company's original forecast was a growth of 31%-37%. Novo Nordisk's stock price in Copenhagen (NOVOB.DC) is currently down 2.35%, deviating from the historical high set on October 12. Novo Nordisk's ADR (NVO) in the US pre-market is up 1.56%. Eli Lilly's stock in the US pre-market is up nearly 1%.